Histone Demethylase

Histone Demethylase

Histone methylation is carried out by methyltransferases and demethylases, two classes of enzymes. While methyltransferases are in charge of creating methylation patterns, demethylases have the ability to remove methyl groups from proteins other than histones. Histone demethylases interact with methylated sites on non-histone proteins, such as p53, in addition to targeting methylated sites on histone tails.
Due to their regulatory functions in chromatin organization and their close ties to diseases like cancer and mental disorders, histone lysine demethylases (KDMs) are of interest as drug targets.

Demethylase JMJD1A, also known as KDM3A, eliminates methyl from histone lysine H3K9. It is crucial for many cellular functions, such as spermatogenesis, energy metabolism, stem cell control, and gender expression.

A histone demethylase known as Jumonji domain-containing 3 (Jmjd3) has been discovered, and it specifically catalyzes the removal of methylation from H3K27me3.

Histone Demethylase related products

Structure Cat No. Product Name CAS No. Product Description
V56074 (1R,2S)-NCD38 TFA 2078047-42-2
V52401 Arborinine 5489-57-6
V2982 AS8351 796-42-9 AS8351 is a potent inhibitor of KDM5B (lysine-specific histone demethylase 5B) which plays an important role in maintaining cancer stem cells and justifies the rationale for studying the effects of continuous inhibition of this epigenetic factor in cancer.
V77191 Bomedemstat dihydrochloride (IMG-7289 dihydrochloride)
V56076 CBB1003 hydrochloride 2070015-02-8
V17664 CBB1007 1379573-92-8 CBB-1007 is a novel and potent Lysine-specific demethylase 1 (LSD1) inhibitor (IC50 = 5.27 μM for hLSD1)with anticancer activity.
V56067 CBB1007 hydrochloride 2070014-96-7
V52955 CBB1007 trihydrochloride 2070015-03-9
V75857 cis-4-Br-2,5-F2-PCPA (S1024) 2821068-03-3
V2606 CPI-455 1628208-23-0 CPI-455 is a novel, potent andspecific inhibitor of the KDM5demethylase which catalyzes the demethylation of histone H3 on lysine 4 (H3K4) and is required for the survival of drug-tolerant persister cancer cells (DTPs).
V10836 CPI-455 hydrochloride 2095432-28-1
V2936 DDP-38003 dihydrochloride 1831167-98-6 DDP-38003 dihydrochloride, atranylcypromine (TCPA) derivative, is a novel, potent and orally bioavailable inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1).
V77096 DDP-38003 trihydrochloride
V56182 Eicosapentaenoic Acid-d5 (EPA-d5; Timnodonic acid-d5) 1197205-73-4
V21424 Furazolidone 67-45-8 Furazolidone is a nitrofuran derivative with potent antiprotozoal and antibacterial activity.
V80080 FY-21
V52030 GSK 690 Hydrochloride 2436760-79-9
V4761 GSK J4 HCl 1797983-09-5 GSK J4 (GSK-J4) is a novel,cell permeable, and potent prodrug of GSK J1 with anti-inflammatory effects.
V3540 GSK-690 2101305-84-2 GSK 690 is a novel, potent and selective reversible inhibitor of lysine specific demethylase 1(LSD1), with aKdvalue of 9 nM and a biochemicalIC50of 37 nM.
V45816 GSK-690 HCl GSK-690 hydrochloride is a selective reversible inhibitor of lysine specific demethylase 1(LSD1) with anticancer activity.
Contact Us